Key facts
- Genknowme’s last known valuation is $10.6M (Apr 2025).
- It has raised $3.0M.
- Notable investors include Venture Kick, Biopole, Fondation pour l'Innovation Technologique, Future of Health Grant, Innopeaks — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Genknowme
- ·The full record, as it builds
Funding rounds
No funding rounds for Genknowme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genknowme
Provider of epigenetic health assessment services intended for preventive health monitoring purposes. The company applies blood-based epigenetic analysis to evaluate lifestyle-related biological indicators, examines markers associated with aging and stress, operates within certified laboratory procedures, and delivers structured reports for professional interpretation, enabling healthcare practitioners to guide individuals toward a data-driven understanding of their long-term health status.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2019
- Employees
- 9
- Website
- genknowme.com/
- Ownership
- Privately Held (backing)
Genknowme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genknowme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genknowme in its N-PORT filings yet. We sweep new filings monthly.